ECSP088922A - Derivados de amino-tiazol y sus usos como agentes antibacterianos - Google Patents

Derivados de amino-tiazol y sus usos como agentes antibacterianos

Info

Publication number
ECSP088922A
ECSP088922A EC2008008922A ECSP088922A ECSP088922A EC SP088922 A ECSP088922 A EC SP088922A EC 2008008922 A EC2008008922 A EC 2008008922A EC SP088922 A ECSP088922 A EC SP088922A EC SP088922 A ECSP088922 A EC SP088922A
Authority
EC
Ecuador
Prior art keywords
tiazol
derivatives
amino
antibacterial agents
prevention
Prior art date
Application number
EC2008008922A
Other languages
English (en)
Inventor
Lewis Whitehead
Michael A Patane
Matthew J Lamarche
Simon Bushell
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38645676&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088922(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP088922A publication Critical patent/ECSP088922A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente solicitud describe compuestos orgánicos que son útiles para el tratamiento, la prevención, y/o la mejora de enfermedades
EC2008008922A 2006-05-31 2008-11-28 Derivados de amino-tiazol y sus usos como agentes antibacterianos ECSP088922A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80969306P 2006-05-31 2006-05-31

Publications (1)

Publication Number Publication Date
ECSP088922A true ECSP088922A (es) 2008-12-30

Family

ID=38645676

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008922A ECSP088922A (es) 2006-05-31 2008-11-28 Derivados de amino-tiazol y sus usos como agentes antibacterianos

Country Status (31)

Country Link
US (2) US7851439B2 (es)
EP (2) EP2044101B1 (es)
JP (1) JP5351014B2 (es)
KR (1) KR101061658B1 (es)
CN (2) CN102399260B (es)
AR (1) AR060977A1 (es)
AU (1) AU2007255025B2 (es)
BR (1) BRPI0711885A2 (es)
CA (1) CA2650133A1 (es)
CL (1) CL2007001542A1 (es)
CR (1) CR10430A (es)
DK (1) DK2044101T3 (es)
EC (1) ECSP088922A (es)
ES (1) ES2441993T3 (es)
HR (1) HRP20140055T1 (es)
IL (1) IL194880A (es)
MA (1) MA30485B1 (es)
MX (1) MX2008015216A (es)
MY (1) MY146920A (es)
NO (1) NO20085032L (es)
NZ (1) NZ572154A (es)
PE (2) PE20080103A1 (es)
PL (1) PL2044101T3 (es)
PT (1) PT2044101E (es)
RU (1) RU2450015C2 (es)
SI (1) SI2044101T1 (es)
TN (1) TNSN08496A1 (es)
TW (2) TW201107337A (es)
UA (1) UA95627C2 (es)
WO (1) WO2007142986A2 (es)
ZA (1) ZA200808449B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080103A1 (es) 2006-05-31 2008-04-03 Novartis Ag AMINOTIAZOLES COMO MODULADORES DEL FACTOR DE ELONGACION EF-Tu
PT2097423E (pt) 2006-12-20 2011-06-01 Novartis Ag Macrociclos de aminotiazole, seu uso como compostos antibacterianos e processos para a sua produção
AU2008258639B2 (en) 2007-06-04 2012-07-05 Novartis Ag Macrocycles and their uses
KR101187111B1 (ko) * 2007-12-12 2012-09-28 노파르티스 아게 아미노티아졸 및 그의 용도
AU2012261611B2 (en) * 2007-12-12 2014-05-15 Novartis Ag Aminothiazoles and their uses
WO2014167371A1 (en) * 2013-04-12 2014-10-16 Naicons S.C.A.R.L. Analogs of the antibiotic aminothiazole ge2270
CN106366168B (zh) * 2016-08-26 2020-09-15 上海交通大学 羊毛硫肽类抗菌肽及其脱氢衍生物的制备方法
CN107243008B (zh) * 2017-04-13 2021-03-30 中国科学院广州生物医药与健康研究院 吡唑并[1,5-a]吡啶类化合物的新应用及一种治疗脓肿分枝杆菌感染的组合物
CN113219078B (zh) * 2021-03-25 2022-12-16 广东产品质量监督检验研究院（国家质量技术监督局广州电气安全检验所、广东省试验认证研究院、华安实验室） 一种生活用纸制品中17种有机抗菌剂快速筛查方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202241A (en) * 1988-09-09 1993-04-13 Gruppo Lepetit S.P.A. Antibiotic GE 2270
EP0406745B1 (en) * 1989-07-04 1995-01-25 GRUPPO LEPETIT S.p.A. Antibiotic GE 2270 factors A1, A2, A3 and H
ES2071143T3 (es) * 1990-03-08 1995-06-16 Lepetit Spa Factores b1, b2, c1, c2, d1, d2, e y t del antibiotico ge 2270.
IL100572A (en) * 1991-01-03 1997-01-10 Lepetit Spa Amides of antibiotic ge 2270 factors their preparation and pharmaceutical compositions containing them
DE69224497T2 (de) * 1991-08-30 1998-07-02 Biosearch Italia Spa Faktor C2a des Antibiotikums CE 2270
US5882900A (en) * 1992-09-10 1999-03-16 Gruppo Lepetit S.P.A. Process for the selective increase of production of antibiotic GE 2270 factor a by adding vitamin B12 to nutrient medium
DK0675900T3 (da) 1992-12-22 1998-03-09 Biosearch Italia Spa Antibiotika GE 37468 A, B og C
JPH10508476A (ja) 1994-11-08 1998-08-25 グルポ・レペチツト・エス・ピー・エイ 抗生物質ｇｅ２２７０因子ｄ▲下２▼を得るための微生物変換法
ES2161344T3 (es) * 1995-02-07 2001-12-01 Biosearch Italia Spa Derivados oxazolin-amidicos basicos de los antibioticos ge2270 y similares.
SI0801655T1 (en) * 1995-02-07 1998-08-31 Biosearch Italia S.P.A. Basic proline-amide derivatives of ge 2270 and ge 2270-like antibiotics
HUP9901007A3 (en) * 1996-02-14 1999-11-29 Vicuron Pharmaceuticals Inc Ki Derivatives of antibiotic ge2270 factors c2a, d2 and e
JPH1059997A (ja) * 1996-08-22 1998-03-03 Microbial Chem Res Found アミチアマイシンアミド誘導体
BR0305070A (pt) 2002-06-17 2004-09-21 Vicuron Pharm Inc Uso de derivado amida de ge 2270 fator a3 para tratamento da acne
WO2006086012A2 (en) 2004-09-22 2006-08-17 Merck & Co., Inc. Antibiotic compound
PE20080103A1 (es) * 2006-05-31 2008-04-03 Novartis Ag AMINOTIAZOLES COMO MODULADORES DEL FACTOR DE ELONGACION EF-Tu
KR101187111B1 (ko) * 2007-12-12 2012-09-28 노파르티스 아게 아미노티아졸 및 그의 용도

Also Published As

Publication number Publication date
CA2650133A1 (en) 2007-12-13
TNSN08496A1 (en) 2010-04-14
JP5351014B2 (ja) 2013-11-27
MA30485B1 (fr) 2009-06-01
NZ572154A (en) 2011-12-22
PE20121011A1 (es) 2012-08-25
RU2008150785A (ru) 2010-07-10
AU2007255025B2 (en) 2011-07-14
EP2322536A2 (en) 2011-05-18
WO2007142986A2 (en) 2007-12-13
HRP20140055T1 (hr) 2014-02-14
JP2009538914A (ja) 2009-11-12
HK1127614A1 (en) 2009-10-02
CN102399260A (zh) 2012-04-04
WO2007142986A3 (en) 2008-04-10
AU2007255025A1 (en) 2007-12-13
EP2044101A2 (en) 2009-04-08
UA95627C2 (ru) 2011-08-25
DK2044101T3 (da) 2014-01-13
US20100267757A1 (en) 2010-10-21
NO20085032L (no) 2008-12-16
CL2007001542A1 (es) 2008-03-14
SI2044101T1 (sl) 2014-01-31
CR10430A (es) 2009-01-15
TWI342310B (en) 2011-05-21
MX2008015216A (es) 2008-12-12
KR20090006869A (ko) 2009-01-15
PE20080103A1 (es) 2008-04-03
PT2044101E (pt) 2014-01-03
US20080221142A1 (en) 2008-09-11
KR101061658B1 (ko) 2011-09-01
TW201107337A (en) 2011-03-01
ES2441993T3 (es) 2014-02-07
US7851439B2 (en) 2010-12-14
IL194880A (en) 2015-02-26
MY146920A (en) 2012-10-15
CN101454337A (zh) 2009-06-10
EP2044101B1 (en) 2013-10-09
EP2322536A3 (en) 2011-11-30
BRPI0711885A2 (pt) 2012-03-06
IL194880A0 (en) 2011-08-01
ZA200808449B (en) 2014-12-23
PL2044101T3 (pl) 2014-03-31
AR060977A1 (es) 2008-07-23
CN102399260B (zh) 2015-04-15
RU2450015C2 (ru) 2012-05-10
TW200811189A (en) 2008-03-01

Similar Documents

Publication Publication Date Title
CR10433A (es) Compuestos organicos y sus usos
CR10336A (es) Compuestos organicos y sus usos
UY32123A (es) Derivados de n - (sustituido) - 4 - (but-2-iniloxi) - benzamida, sus racematos, diastereòmeros, enantiòmeros y las sales de los mismos y aplicaciones
ECSP088922A (es) Derivados de amino-tiazol y sus usos como agentes antibacterianos
UY32551A (es) Compuestos peptidomiméticos de sulfamida y usos antivirales de los mismos
CR10310A (es) Compuestos nuevos
UY32554A (es) Compuestos peptidomiméticos de sulfonamida y usos antivirales de los mismos
CR20150217A (es) Inhibidores de histona demetilasas
CL2015002519A1 (es) Composiciones antimicrobiales y procedimientos de uso relacionados.
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
ECSP10010042A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
GT200800187A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
CR11430A (es) 4-pirazolil-n-arilpirimidin-2-aminas y 4-pirazolil-n-heteroarilpirimidin-2-aminas como inhibidores de cinasas janus
ECSP088536A (es) DERIVADOS DE PIRIDO-, PIRAZO- Y PIRIMIDO-PIRIMIDINA COMO INHIBIDORES DE mTOR
SV2009003307A (es) Quinazolinas para la inhibicion de pdk1
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
ECSP099836A (es) Macrociclos y sus usos
ECSP088176A (es) Derivados de azinil-3-sulfonilindazol como ligandos de5-hidroxitriptamina-6
DOP2006000087A (es) Compuestos heteroaromaticos acilaminobiciclicos y sus usos
AR060402A1 (es) Compuestos organicos y sus usos
CU20100119A7 (es) Compuestos orgánicos de aminotiazoles
ECSP088930A (es) Derivados de benzoxazol y benzotiazol como ligandos de
UY31424A1 (es) Compuestos de 2,3-dihidro-benzofurano
ECSP088789A (es) Derivados de sulfonil-3-heterociclilindazol como ligandos de 5-hidroxitriptamina-6
GT200800263A (es) Derivados de amino-tiazol y sus usos como agentes antibacterianos